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Finding the Proverbial Needle: Non-targeted Screening of Synthetic Opioids in 
Equine Plasma 
Synthetic opioids are a class of compounds that are of particular concern due to their high 
potency and potential health impacts. With the relentless emergence of new synthetic opioid 
derivatives, non-targeted screening strategies are required that do not rely on the use of library 
spectra or reference materials. In this study, product ion searching, and Kendrick mass defect 
analysis were investigated for non-targeted screening of synthetic opioids. The estimated 
screening cut-offs for these techniques ranged between 0.05 and 0.1 ng/mL. These techniques 
were designed to not be reliant on a particular vendor’s software, meaning that they can be 
applied to existing drug screening protocols, without requiring the development and validation 
of new analytical procedures. The efficacy of the developed techniques was tested through 
blind trials, with spiked samples inserted amongst authentic plasma samples, which 
demonstrated the usefulness of these methods for high-throughput screening. The use of a 
non-targeted screening workflow that contains complementary techniques can increase the 
likelihood of detecting compounds of interest within a sample, as well as the confidence in 
detections that are made. 
Keywords: synthetic opioids; fentanyl; new psychoactive substances; non-targeted screening; 
HRMS 
1. Introduction 
Opioids are compounds that produce analgesic effects through the binding to specific opioid 
receptors 1. These compounds emulate the effects of endogenous opioid peptides, such as 
endorphins, enkephalins and dynorphins, which are present in the central and peripheral nervous 
systems as neurotransmitters and neuromodulators 2. Fentanyl is probably the most well-known 
synthetic opioid and has been used as a medication for pain management since the 1960s 3. Fentanyl 
and its analogues, however, have often been misused in place of heroin due to its lower cost 4, and 
there is an increasing trend of fentanyl and its analogues, and other synthetic opioids, being mixed 
into heroin or sold as prescription opioids 5. Alongside the fentanyl analogues, there are a number of 
other novel synthetic opioids (NSOs) emerging onto the illicit drug market. The most prolific of 
these NSOs are the AH and U series’, which were originally developed as new opioid agonists, but 
were never brought to the market for human use 6. Synthetic opioids have recently emerged as a 
drug class of particular concern due to the health issues caused by their incredibly high potency. 
The proliferation of fentanyl analogues, along with other NSOs, also poses a significant challenge 
for toxicologists, with these compounds accounting for 29% of newly identified new psychoactive 
substances (NPS) in 2017 7. 
In addition to the significant human health risks posed by these compounds, it has been found that 
opioids have a propensity for causing stimulant-like effects in horses, in conjunction with their 
conventional pain depressing properties 8-10. This stimulant effect was found to be common to all 
narcotic analgesics 8, however it has been theorized that κ-opioid agonists should provide analgesia 
without stimulation 11. The effect of the κ-agonist U-50488 on horses was evaluated and it was 
found that, while there was slight stimulation, it was markedly less than potent μ-agonists, such as 
fentanyl 11. The stimulant effects have been confirmed to be the result of action at the opioid 
receptors, as administration of opioid receptor antagonists, such as naloxone, supress the 
stimulation 8,12. This combination of analgesic and stimulant properties makes synthetic opioids a 
target of importance from an equine anti-doping perspective. Currently in Australia, there is only an 
established cut-off concentration for Butorphanol at 0.01 ng/mL in plasma. The presence of any 
other synthetic opioid, regardless of concentration, is prohibited in equine racing. In 2015, the New 
York Equine Drug Testing Program reported its first positive detection of AH-7921 in a post-race 
sample 13. This shows that novel synthetic opioids have started to encroach into the racing industry 
and reinforces the importance of employing up-to-date screening techniques in anti-doping 
laboratories around the world. 
The continual evolution of the illicit drug market necessitates the development of non-targeted 
screening strategies. While there have been numerous analytical methods developed to detect 
synthetic opioids 3,14-19, these methods are often designed using multiple reaction monitoring 
(MRM), which needs to be optimised using certified reference materials (CRMs) for the specific 
analytes included in the assay. There is often a considerable delay between early use of new 
substances and the availability of CRMs, therefore these strategies need to be able to function 
without relying on CRMs or library spectra 20. Previous collision-induced dissociation (CID) work 
has shown that different groups of synthetic opioids demonstrate certain class-specific 
fragmentation patterns 21, which provides an interesting avenue for the development of non-targeted 
screening strategies. Noble et al. 22 demonstrated that this approach shows promise, through the 
development of a data-independent screening strategy for 50 fentanyl analogues, taking advantage 
of these class-specific cleavages. Preliminary work has also been conducted to expand this strategy 
to the other classes of synthetic opioids 21. Data-independent acquisition (DIA) has an advantage 
over traditional data-dependent acquisition (DDA) methods in that it can collect the product ions of 
all present precursor ions in a single scan, providing full scan MS/MS data 20,22. While this can lead 
to the production of ‘chimeric spectra’, where the software cannot associate a product ion to a 
particular precursor ion 23, the presence of characteristic product ions can be used to identify 
suspicious samples for further analysis. 
In order to interrogate the large amount of data provided by high-resolution mass spectrometry 
(HRMS), various filtering and extraction methods are required to highlight peaks of potential 
interest. The use of mass defect filtering (MDF) was first reported by Grabenauer et al. who applied 
it to the analysis of synthetic cannabinoids in herbal products and were able to detect a compound 
that was not visible in the total ion chromatogram (TIC) 24. The mass defect of a particular 
compound is defined as the difference between its exact mass and its nominal integer mass 25,26. 
Compound classes often have similar mass defects, or specific trends with increasing mass, and 
therefore MDF can be used to selectively filter out related compounds 25. A sub-type of MDF, 
known as Kendrick mass defect (KMD), may also be beneficial for the development of non-targeted 
screening methods. The Kendrick mass scale allows for the recognition of a group of compounds 
that differ by a specific repeating mass unit 25,27. 
The use of KMD filtering has also been investigated for drug screening. Anstett et al. 28 explored 
the application of KMD filtering to the screening of different phenethylamine classes, including  
2C-, aminopropylbenzofuran and 2,5-dimethoxy-N-(2-methoxybenzyl) phenethylamines. The 
authors successfully implemented KMD filters that were able to distinguish between compounds 
from the different classes of phenethylamines that were analysed 28. If similar filters could be 
developed for the different classes of synthetic opioids, this technique could prove a valuable asset 
in the development of potentially complementary non-targeted screening methods for the detection 
of these compounds. 
This study presents a proof-of-concept for the development of a toolbox of complementary 
techniques demonstrating potential for the non-targeted screening of synthetic opioids in equine 
plasma, which may also be applicable to other biological matrices. These techniques focus on the 
‘back end’ data processing and data mining techniques, which allows them to be used in 
conjunction with routine acquisition methods, without the need for laboratories to develop and 
validate new instrumental analyses. 
2. Experimental 
2.1. Solvents and Reagents 
All solvents used were liquid chromatography-mass spectrometry (LC-MS) grade. Acetonitrile, 
ethyl acetate and methanol were obtained from Merck (Darmstadt, Germany). Ammonium acetate 
and trichloroacetic acid were obtained from Sigma-Aldrich (Castle Hill, NSW, Australia). Acetic 
acid was obtained from Ajax Chemicals (Sydney, NSW Australia). Ultrapure-grade water (18.2 
MΩ.cm) was obtained from a Smart2Pure ultrapure water system (Thermo Scientific, 
Langenselbold, Hungary). 
Fentanyl citrate was purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). Hydrochloride 
salts of acetyl fentanyl and AH-7921, along with a neat solid of U-50488, manufactured by Cayman 
Chemical (Ann Arbor, MI, USA), were purchased from Sapphire Bioscience (Redfern, NSW, 
Australia). Carfentanil citrate was purchased from Janssen Pharmaceuticals (North Ryde, NSW, 
Australia). 
2.2. Sample Preparation 
Blank plasma was obtained from blood samples collected in Lithium Heparin Vacutainers 
purchased from BD (Mississauga, ON, Canada) from thoroughbred horses following approval of 
the Racing NSW Animal Care and Ethics Committee (ARA 71). 
Spiked equine plasma samples were prepared at varying concentrations to determine the 
effectiveness of the examined detection methods in an authentic biological matrix. A mixed 
standard containing fentanyl, acetyl fentanyl, carfentanil, AH-7921 and U-50488 was prepared at a 
concentration of 200 ng/mL in methanol. The representative panel of compounds used in this study 
were chosen to demonstrate the potential of the developed techniques across the range of synthetic 
opioid classes. AH-7921 and U-50488 were chosen specifically due to their relevance to the racing 
industry, with AH-7921 being the first NSO reported in an equine plasma sample and U-50488 
being previously studied to determine the effects of κ-opioid agonists in horses 11. The chemical 
structures of the different opioids used in this study can be found in Figure 1. 
 
Figure 1. Chemical structures of opioids included in the study including acetyl fentanyl (A), 
fentanyl (B), carfentanil (C), AH-7921 (D) and U-50488 (E) 
Two millilitres of blank equine plasma was spiked with the mixed standard to produce a 
concentration range of 0.01 to 10 ng/mL across 13 different samples. This concentration range was 
used to estimate limits of detection (LOD) and screening cut-off levels for the developed 
techniques. Blank samples were also prepared alongside the spiked samples. 
Once an effective screening cut-off level was estimated for each technique, further replicates were 
prepared to verify the consistency of these cut-offs at concentrations of 0.05 and 0.1 ng/mL. For 
each concentration, three sets of samples were prepared from a pooled blank plasma source, with 
seven replicates in each set (n = 21). The sample sets were analysed over different days to account 
for intra-day variability. 
Protein precipitation was performed through the addition of 200 µL of 10% (v/v) trichloroacetic 
acid to each of the samples. The pH of the samples was then adjusted to 3 – 3.5 using hydrochloric 
acid and 3 – 3.5 mL of ultrapure water after which they were centrifuged at 1500 x g for 10 
minutes. Solid-phase extraction (SPE) was completed using XtrackT® Gravity Flow DAU 
Extraction Columns (3 mL column, 200 mg sorbent, UCT Inc., Bristol, USA). The cartridges were 
first conditioned with 3 mL of methanol, followed by 3 mL of ultrapure water, after which the 
samples were loaded (~6 mL). The samples were washed with 3 mL of 0.1 M acetic acid and dried 
using a positive pressure manifold at 70 psi (UCT Inc., Bristol, PA, USA). The cartridges were 
washed with 3 mL of methanol and dried under positive pressure. The analytes were eluted from the 
cartridges using 3 mL of ethyl acetate containing 3% ammonia and 0.5% methanol. 
Following SPE, one drop of 0.1 M methanolic hydrochloric acid was added to each of the eluents 
using a Pasteur pipette (approximately 20 µL) before the solvent was evaporated under a gentle 
stream of N2 at 60 °C. The samples were then reconstituted in one drop of methanol from a Pasteur 
pipette and 100 µL of 10 mM ammonium acetate buffer (pH 3.9), before being transferred to vials 
for LC-HRMS analysis. All samples were stored at 4 °C until analysis. 
2.3. Instrumental Analysis 
Chromatographic separation was achieved on an Agilent Technologies (Santa Clara, CA, USA) 
1290 Infinity II UHPLC, consisting of a high-speed pump (G7120A), multisampler (G7167B, 18 
°C) and thermostat and column compartment (G1316A, 35 °C) coupled to an Agilent Technologies 
6545 quadrupole time-of-flight mass spectrometer (QTOF). All data acquisition was performed 
using Agilent Technologies MassHunter Workstation (Version B.06.01). A sample volume of 1 µL 
was injected onto a Phenomenex (Torrance, CA, USA) Gemini 110 Å C18 LC column (2 x 50 mm, 
5 µm particle size) using a gradient elution method with a flow rate of 0.5 mL/min and a total 
analysis time of 11.5 min. Mobile phase A consisted of a 10 mM ammonium acetate buffer (pH 9) 
and mobile phase B consisted of 0.1% (v/v) acetic acid in acetonitrile. Initial mobile phase 
composition was 99% A, which was held for 2 min before being decreased linearly to 20% A over 
6.5 min. The mobile phase was then returned to 99% A over 3 min. 
The QTOF-MS was operated in positive electrospray ionisation mode (ESI+) with capillary and 
fragmentor voltages of 3500 V and 100 V, respectively. An All Ions MS/MS (DIA) data acquisition 
mode was used with a mass-to-charge (m/z) range of 35 – 1000. Spectra were obtained with an 
acquisition speed of 10 spectra/s and collision energies (CE) of 10, 20 and 40 eV for CID. The 
chromatographic and MS conditions were chosen to mimic the routine analytical method employed 
at the Australian Racing Forensic Laboratory (ARFL) to evaluate the effectiveness of the developed 
detection techniques for an operational purpose.  
2.4. Data Analysis 
All extracted ion chromatograms (EICs) for the product ion searching (PIS) and KMD analysis 
methods were generated using Agilent Technologies MassHunter Qualitative Analysis Software 
(Version B.10.0, Build 10.0.10305.0).  
2.4.1. Targeted Compound Extraction Limit of Detection (LOD) 
The suitability of the analytical method was assessed by performing a targeted extraction on the 
spiked compounds using MassHunter Quantitative Analysis Software (Version 10.0, Build 
10.0.707.0). Spiked samples of decreasing concentrations (10 to 0.01 ng/mL) were evaluated to 
estimate LODs using the targeted extraction method. Precursor and product ion EICs were assessed 
within a mass error of ±10 ppm and a retention time tolerance of ±0.2 min of their known retention 
times 29. Where an EIC was assessed for a targeted compound, the signal-to-noise ratio (S/N) was 
obtained to estimate the LOD where the S/N > 3 30. These estimated values were used for qualitative 
comparison to the proposed non-targeted screening methods to demonstrate the effectiveness of 
these methods. 
2.4.2. Product Ion Searching 
For the PIS technique, EICs were created from several diagnostic product ions identified in a 
previous CID study 21 to screen for potential synthetic opioids present in the samples. The 
diagnostic product ions used for each compound class can be found in Table 1. The masses used 
represent the theoretical masses of each product ion. All EICs were generated with a mass tolerance 
of ±10 ppm. Product ion masses were extracted at the CE (10, 20 or 40 eV) which gave the greatest 
peak intensity. This CE was determined automatically by the data analysis software. 
Table 1. Diagnostic product ions from each compound class used for screening 21. 
Compound Class 
Diagnostic Product Ions (m/z) 
1 2 3 
Fentanyls 105.0704 188.1439 - 
AH Series 172.9561 189.9827 284.0609 
U Series 158.9768 218.0140 298.0766 
 
2.4.3. Kendrick Mass Defect 
When calculating KMD, a normalisation factor is used to ‘correct’ the exact mass of a particular 
compound and give the Kendrick mass. Most commonly, the mass of the CH2 group is used as the 
correction factor. Essentially, the mass of a CH2 group is set to be exactly 14.00000, allowing the 
Kendrick mass of a compound to be calculated (Equation 1) 27. 
𝐾𝑒𝑛𝑑𝑟𝑖𝑐𝑘 𝑚𝑎𝑠𝑠 = 𝐼𝑈𝑃𝐴𝐶 𝑚𝑎𝑠𝑠 ×
14
14.01565
 (Equation 1) 
In this study, the KMD values for each compound were calculated as the difference between the 
Kendrick exact mass and the integer Kendrick mass 25. For example, the Kendrick mass of fentanyl 
is 336.8509, in this case the KMD is 0.8509, as the integer Kendrick mass is 336. 
KMD analysis was conducted using a custom-built program developed by Pasin in the Visual Basic 
for Applications (VBA) environment for Microsoft Excel (named DefectDetect) 31. An averaged 
mass spectrum over a retention time range (0.5 – 8 min) was created for each sample and an m/z and 
intensity list was generated as a Microsoft Excel comma-separated value (.csv) file from these 
spectra. This retention time range was chosen as it is the range within which the analytes of interest 
were expected to elute, based on the representative compounds analysed and the chromatographic 
conditions. The program then calculated the Kendrick masses and mass defects using a 
normalisation factor of CH2 and filtered the results based on a mass range of m/z 200 – 500, a KMD 
tolerance of ± 0.005 Da and mass defect filter of 0.1 – 0.27 Da. Table 2 shows the different KMD 
filters that were used in this study. Examples of the compounds belonging to the different fentanyl 
groups can be found in the Supporting Information (Figure S1). A minimum m/z value was 
populated for each filter and the program only considered masses that varied by a multiple of 14 Da 
from the minimum m/z to account for the difference of CH2 units. An example of the DefectDetect 
interface can be found in the Supporting Information (Figure S2). A copy of DefectDetect can be 
obtained on request from the authors. 
  
Table 2. Kendrick mass defect (KMD) filters used for compound detection. 
Name KMD Minimum m/z 
Fentanyl (amide chain) 0.8510 323 
Fentanyl (cyclic) 0.8380 335 
Fentanyl (F analogues) 0.8215 355 
Carfentanil 0.7916 395 
AH + U Series 0.7510 329 
AH Series 0.8276 295 
 
2.4.4. Non-targeted Workflow 
For each sample, EICs were extracted for the common product ions identified in Table 1, followed 
by the extraction of masses identified by the KMD analysis. The generated EICs from each 
individual technique were first reviewed independently. If a peak of interest was identified by either 
technique, a comparison was made to the results obtained from the complementary technique to 
verify concurrence. 
2.5. Blind Trial Setup 
Blind trials were performed to validate the effectiveness of the detection methods under pseudo-
operational conditions. Single compound spikes were prepared for fentanyl and acetyl fentanyl at 
concentrations of 0.05 ng/mL and 0.5 ng/mL (n = 4). Routine plasma samples from the ARFL were 
included to make a batch containing 20 samples. The ‘Randbetween’ function in Excel was used to 
randomise the positioning of the spiked samples within the worklist, and this randomisation was 
completed by a third party to ensure that the analyst was unaware of which samples were spiked. 
All samples in the worklist were then analysed using the instrument parameters outlined in 2.3 and 
the data was processed using the PIS and KMD analysis methods detailed above. These blind trials 
were conducted on two separate occasions. 
3. Results and Discussion 
3.1. Implementation of Non-targeted Workflow 
Once the data from each sample has been processed using the developed techniques, the results 
from each technique can first be reviewed independently to determine the presence of any possible 
analytes of interest. The results can then be compared with the complementary technique to provide 
further evidence of detection. Observation of retention time-matched peaks in MS1 (KMD) and MS2 
(PIS) may provide strong evidence for the presence of a particular subclass of synthetic opioid. 
Observation of retention time-matched peaks in MS2 that is not corroborated by an extracted MS1 
peak may indicate the presence of a synthetic opioid containing the same core structure with novel 
modifications outside of the determined KMD filters. By implementing screening workflows that 
contain complimentary techniques, it increases confidence that one technique identifies a feature of 
interest and provides stronger evidence for detection when both techniques provide corroborative 
results. 
  
3.2. Application of Screening Techniques 
The applicability of each developed technique to non-targeted screening was evaluated to ensure 
that they were fit-for-purpose. The sensitivity of the techniques to the presence of a spiked 
compound in equine plasma was evaluated to propose an appropriate screening cut-off level. At 
concentrations below this proposed cut-off, it may be possible to detect an analyte of interest, 
however the reliability of detection would be reduced. Additionally, the specificity of these 
techniques was considered to ensure that a sample containing an analyte of interest could easily be 
distinguished from blank plasma samples. 
3.2.1. Product Ion Searching 
In a general screening workflow, detection and putative identification are performed by comparison 
to a spectral library. In some cases, where the fragmentation patterns of novel compounds are 
sufficiently similar to known compounds, these techniques may be used to detect new analogues. 
When increased structural diversity is present within groups of analogues, or only a limited number 
of common product ions are present, simply screening samples against spectral libraries may not be 
sufficient. To improve the situation, the applicability of PIS for the detection of synthetic opioids in 
plasma has been demonstrated previously 21. 
Figure 2 displays EICs from the targeted extraction of selected synthetic opioid precursor ions in a 
spiked plasma sample (0.05 ng/mL), as well as EICs for the common product ions of each opioid 
subclass in both the spiked plasma sample and a matrix blank. It can be seen from the spiked 
sample that there are distinct retention time aligned peaks for each set of common product and 
precursor ions, indicating the presence of an analyte of interest belonging to each of these 
subclasses. In the matrix blank, however, there are no clear peaks detected, which demonstrates 
specificity for this technique. The matrix blank displayed for EICs corresponding to the fentanyl 
analogues showed higher noise compared to the respective EICs for the other two subclasses. This 
is most likely due to the fact that these masses, belonging to the AH and U series opioids, have 
mass defects that are indicative of molecules containing halogens, which are less likely to be 
present in the matrix background than the masses of the common fentanyl product ions. In this 
study, all EICs were extracted within a mass error of ±10 ppm. Given that the masses being 
extracted for the PIS method correspond to the theoretical masses of each ion, this tolerance can be 
altered on a case-by-case basis depending on the mass accuracy required for specific assays. 
 
Figure 2. EICs showing the targeted extraction of known precursor masses showing the detection 
of the spiked compounds in a 0.05 ng/mL spike. The common product ions used for PIS screening 
also showed detection of the same peaks and could be easily distinguished from the matrix blank, 
showing the specificity of the technique. 
From a routine screening perspective, the EICs generated from the common product ions can be 
combined (i.e. a single chromatographic trace that represents multiple m/z values) in MassHunter to 
reduce the amount of data that the analyst must review. If a peak is detected in a sample however, 
separate EICs should be created for that sample to ensure that multiple characteristic ions are 
present. In some instances, a single, high abundance ion can cause a peak to be displayed in the 
combined EIC. Without the presence of other diagnostic product ions, it cannot be confidently 
stated whether that ion is present from a compound of interest or if it is extraneous from an 
unrelated background compound. Alternatively, overlaid EICs for the individual product ions can 
be viewed for the same purpose. Figure 3 shows an example of such a case, where the overlaid EIC 
for common product ions for the U series show detection of all 3 ions, with decreasing intensities, 
within the same peak (left). On the other hand, Figure 3b shows a large peak at m/z 158.9768, while 
the EICs at m/z 218.0140 and 298.0766 only show minor peaks at significantly lower abundances 
barely noticeable on the overlaid chromatogram, which do not have the same retention time and, 
therefore, cannot be attributed to the same compound. In this case, the lack of corroborating ions 
means that the peak at m/z 158.9768 cannot be confidently attributed to a U series compound, as 
there may be a background compound present in the equine plasma with this mass. 
  
 
Figure 3. Example overlaid EICs for common U series product ions m/z 158.9768 (red), 218.0140 
(blue) and 298.0766 (green) from a spiked plamsa sample with 0.05 ng/mL U-50488 (A) and a 
blank sample (B) 
The screening cut-off of this technique was found to be 0.05 ng/mL 21. This cut-off level was 
determined by the concentration at which the common product ions for the majority of analytes in a 
particular class had a S/N > 3. Below this concentration, some product ions may still be detected in 
a sample, which can give some indication that an opioid may be present. Some product ions, 
however, were not observed. If the EICs generated from a sample only reveal a single product ion, 
then a lower confidence in the detection occurs. Some of the product ions that were found to be 
common to the different subclasses of synthetic opioids are not specific to these compounds alone. 
For example, the fentanyl product ion at m/z 105.0704 will likely be present in any compound 
containing a phenylethyl group. While this ion constitutes a good marker for fentanyl analogues in 
combination with other common product ions, its presence alone would not necessarily be 
indicative of these compounds. Therefore, care should be taken when interpreting results of samples 
that may have concentrations below this cut-off, where some common product ions are not detected. 
3.2.2. Kendrick Mass Defect Analysis 
KMD analysis using the DefectDetect program operates using an imported mass list containing m/z 
and intensity values generated from an averaged mass spectrum over a given retention time range. 
The program will then calculate the Kendrick mass and KMD of each identified m/z value and filter 
the results based on the user-defined parameters. An example of the results table can be found in the 
Supporting Information (Figure S3). Once the filtered list has been generated, EICs can be created 
for the selected masses to determine if there is a peak present or if the mass has arisen from 
background noise. It is possible to include intensity filters in the DefectDetect parameters, however 
it was decided that the absolute intensity can be variable depending on the instrument and analytical 
method used and, as such, this filter was not included in the analysis. 
Figure 4 shows example EICs for some of the filtered masses detected by KMD analysis of a 
plasma sample spiked with 0.1 ng/mL of a mixed standard, as well as the results table generated for 
this sample. The results tables generated by the DefectDetect program are colour coded to 
correspond to the individual filters used in the analysis. It can be seen in these chromatograms that 
the masses correlating to the spiked samples show well-defined peaks at relatively high abundances, 
in the order of 103 and 104. On the other hand, the EICs at m/z 323.1914 and 335.2181 have much 
lower abundances and significantly more noise along the baseline, indicating that they could be 
present due to the matrix background. Additionally, Figure 4 shows the top six masses identified by 
performing KMD analysis on a blank matrix sample. Once again, the EICs generated are noisy and 
have quite a low abundance, suggesting that there is no meaningful detection of an analyte of 
interest. This demonstrates the specificity of KMD analysis for analytes of interest, as they can be 
easily differentiated from background noise. 
 
Figure 4. EICs for some of the identified masses from DefectDetect showing selectivity to the 
spiked compounds in comparison to the blank (A) and the results table given by DefectDetect for 
the spiked sample (B). The detected class for each mass in the results table is given according to the 
filters listed in Table 2. AC: Amide Chain, Cy: Cyclic, FA: F analogues. 
A number of different KMD tolerances were trialled in order to determine the best balance between 
reliability of detection and total number of filtered results. It is important to note that this technique 
operates using a list of averaged masses for each sample, therefore the accuracy of the calculated 
KMD values is dependent on the accuracy of the instrument used. In this case, the tolerance used 
for routine KMD analysis may require adjustment to suit instrument capabilities. For this study, it 
was determined that a tolerance of ± 0.005 Da was fit for purpose. When optimising the parameters 
for this detection technique, a reliability of ≥ 95% for each spiked compound at a concentration of 
0.1 ng/mL was deemed to be a suitable cut-off. The reliability of detection was evaluated by 
analysing three sets of spiked samples, each containing seven replicates (n = 21), and ensuring that 
the spiked compounds were being detected by the KMD filters applied. In addition, an arbitrary 
threshold of 20 filtered results was decided upon to limit the amount of data that needed review. It 
is important to note that, for the purpose of this proof-of-concept study, the retention times of the 
peaks identified by the KMD analysis were compared to the known retention times of the spiked 
compounds (within a tolerance of ± 0.2 min 29) to ensure that the suspected compound was being 
correctly identified. 
In addition to the KMD filters, an MDF can be applied to further reduce the number of filtered 
results. The mass defect range for a large number of synthetic opioids fell within a range of 0.10 – 
0.27 Da, allowing some variation either side to account for mass tolerance and different structures. 
This range is broad, and by itself would not mean much. When it was applied on top of the other 
filters that were already in place, however, it significantly reduced the number of results that were 
obtained for each sample (50 – 63% reduction), while not affecting the reliability of the detection of 
the spiked compounds. Table 3 provides a summary of one set of the spiked samples showing the 
reliability and variation in the number of filtered results obtained. These results demonstrate that 
KMD analysis can reliably detect the presence of an analyte of interest, while still returning a 
reasonable number of results that need to be reviewed by generating EICs in an operational 
environment. Across all the 21 samples analysed, the spiked compounds within the defined KMD 
filters were detected in every sample. 
Table 3. KMD analysis of one set of 0.1 ng/mL samples, showing consistent detection of analytes 




Fentanyl AH-7921 Carfentanil 
Filtered 
Results 
A ✓ ✓ ✓ ✓ 11 
B ✓ ✓ ✓ ✓ 15 
C ✓ ✓ ✓ ✓ 13 
D ✓ ✓ ✓ ✓ 13 
E ✓ ✓ ✓ ✓ 14 
F ✓ ✓ ✓ ✓ 16 
G ✓ ✓ ✓ ✓ 12 
 
3.3. Blind Trial 
In order to evaluate the effectiveness of these techniques under more realistic conditions, the blind 
trial was completed on two different occasions using the PIS and KMD analysis methods to provide 
complementary detection. On both of these occasions, the higher concentration spikes (0.5 ng/mL) 
were quite clearly detectable within the dataset. Figure 5 shows the PIS results for the acetyl 
fentanyl spikes, along with a negative sample and the matrix blank. 
 
Figure 5. PIS results obtained from the blind trial showing detection of both monitored ions in the 
0.5 ng/mL spike and only detection of the m/z 188.1439 ion in the 0.05 ng/mL spike 
There are distinct peaks present at relatively high abundances for both the m/z 105.0704 and 
188.1439 product ions expected from a fentanyl derivative. Importantly, the peaks present in the 0.5 
ng/mL spike can be clearly differentiated from both the matrix blank and the negative sample 
presented in Figure 5. While these peaks could not specifically identify acetyl fentanyl in a routine 
sample, they could be used to identify the sample as possibly containing a fentanyl derivative for 
further putative identification. 
In the 0.05 ng/mL acetyl fentanyl spike (Figure 5), one of the common product ions at m/z 105.0704 
was not detected in the sample. Given that the m/z 105.0704 ion is common for organic molecules 
containing a phenethyl moiety, it is reasonable to suggest that this ion may be more commonly 
present in the background of biological matrices. This is further demonstrated by the fact that EICs 
generated for m/z 105.0704 tend to have a noisier baseline, as seen in Figures 2 and 5. At lower 
concentrations, therefore, it is possible that the presence of this common fentanyl product ion is 
masked by the background evident from the sample matrix. This can affect the confidence with 
which the presence of a compound of interest can be indicated. This again highlights the benefit of 
using complementary techniques. In addition to one technique being able to detect compounds that 
are missed by the other, the results from one detection technique can be used to corroborate the 
findings from another. 
Figure 6 presents the KMD results for each of the spiked acetyl fentanyl standards compared to 
their PIS results. In both spiked samples, the KMD analysis identified a peak with comparable 
retention time at the expected molecular ion mass of acetyl fentanyl (within a mass error of ± 10 
ppm). From these results, it can also be seen how the other masses identified by the KMD analysis 
can be eliminated by reviewing their EICs and comparing with the PIS results. While the detection 
of the common product ions at m/z 105.0704 and 188.1439 cannot indicate the specific identity of 
the compound detected, the supporting KMD results identify the mass of the suspected molecular 
ion, which can be used for further putative identification work. 
 
Figure 6. PIS results for the spiked acetyl fentanyl samples (A) compared with the associated KMD 
results for each sample (B) 
Interestingly, in the lower concentration (0.05 ng/mL) samples used for the blind trial, the KMD 
analysis was able to show the acetyl fentanyl peak even though this sample fell below the proposed 
screening cut-off. A cut-off of 0.1 ng/mL was proposed as this is the concentration where the 
reliability of detection with this technique was > 95%. It is, of course, possible that detections may 
be made below this concentration, as demonstrated in this blind trial, however, the reliability of 
identifying all samples with compounds of interest at lower concentrations would be affected. The 
spiked fentanyl samples at both concentrations (0.05 and 0.5 ng/mL) were also identified among the 
dataset and it was found that they followed the same trends highlighted by the acetyl fentanyl 
results presented (Figures S4 and S5). 
While the higher concentration samples (0.5 ng/mL) were clearly identified with corroborative 
evidence from both complementary techniques, the lower concentration samples (0.05 ng/mL) 
lacked the identification of the common product ion at m/z 105.0704. In practice, this can be used to 
create ‘confidence levels’ when it comes to the detection of compounds of interest. When all 
components of a detection workflow are in agreement, as seen in Figure 6 for the 0.5 ng/mL spike, 
a high degree of confidence can be placed in the detection of a given compound. On the other hand, 
when no indication of an exogenous substance is provided by either technique, it can be said that 
the compounds of interest are not present. A compromise position can also exist, where some 
components of the detection workflow indicate the presence of a compound, but others do not, as 
seen in Figure 6 for the 0.05 ng/mL spike. In these cases, laboratories can set out a standard 
operating procedure about what samples should be subject to further analysis. 
3.4. Comparison of Techniques 
The major limitation of both techniques is the structural diversity of the opioids themselves. While 
the identified diagnostic product ions cover a large majority of the known structures of synthetic 
opioids, it is always possible that new structures will arise that will not lead to the formation of 
these ions. As has been demonstrated previously 21, certain fentanyl analogues that contain 
additional substitutions on their piperidine ring, such as carfentanil, do not give rise to the same 
diagnostic product ions as the majority of fentanyl analogues. Carfentanil, in particular, presents the 
common product ion at m/z 105.0704 similar to other fentanyl derivatives (Figure 7), albeit at a 
lower abundance. This compound, however, does not display the other common product ion at m/z 
188.1439. This means that screening using the proposed PIS method may not identify samples 
where this compound is present. It is possible to include further diagnostic product ions that are 
more specific to different compounds, however this begins to create a large list of possible masses 
for extraction, comparable to targeting a wide array of theoretical opioid analogue precursor m/z 
values, which introduces difficulties for high-throughput screening. The benefit of using a smaller 
number of product ions to encompass a larger range of compounds is that there is much less data for 
the analyst to review, making the screening easier from an operational perspective. While there are 
certainly limitations to the PIS technique, the broad array of compounds that it does encompass, 
along with the opportunity for a similar technique to be applied to different compound classes 32, 
demonstrates the applicability of this approach to a non-targeted screening workflow. 
 
Figure 7. EICs showing common fentanyl product ions at m/z 105.0704 and 188.1439 (A) showing 
a peak for carfentanil at a lower abundance at m/z 105.0704 (B) but not m/z 188.1439 
The structural diversity of the opioids also presents challenges for KMD analysis, which is 
particularly evident for the fentanyl analogues. This technique works well for compounds that 
contain repeating units, however if multiple different changes are present in the chemical structure, 
it will change the KMD value, meaning that it may no longer fall within the filter parameters. This 
drawback has been somewhat mitigated by the inclusion of multiple filters for different subgroups 
of fentanyl analogues, which can then capture a representative group of the known compounds in 
this group. This means that a balance needs to be maintained between targeted and non-targeted 
approaches by selecting the right number of filters appropriate to a specific application. When 
screening for high priority compounds, such as carfentanil, specific filters can be added to detect 
these compounds, however, for the purpose of non-targeted screening, this should be used 
sparingly. In comparison to the fentanyl analogues, a larger portion of AH and U opioids are 
covered by a small number of filters, however there are still some compounds, such as U-50488, 
that may fall outside of these filters. 
These drawbacks should not detract from the application of this technique. Given that DefectDetect 
operates using an averaged mass list, it is vendor software agnostic. This means that it can be 
implemented into a routine workflow regardless of the type of instrument used in a laboratory, so 
long as an averaged mass list can be generated. In addition, this technique has been previously 
shown to be useful for other drug classes, namely cathinones and phenethylamines 28,31. The filters 
used for the KMD analysis are user-defined, meaning that multiple different drug classes can be 
combined into a single output, depending on the priorities of the specific laboratory. In this study, 
KMD values were corrected for a repeating CH2 unit, which was found to be most appropriate for 
synthetic opioids, however different correction factors may be applied to more efficiently detect 
different drug classes. It is important when applying this technique to new compound groups that 
common structural features are identified and different correction factors are evaluated to determine 
the optimal filters to use, which encompass the broadest range of compounds. 
These non-targeted screening methods were applied to 157 race-day equine plasma samples 
obtained by the ARFL during the 2019 Autumn Carnival. These samples were analysed using the 
routine screening method in place at ARFL before being subjected to the non-targeted workflow. 
While these samples did not return any positive detections with the applied methods, it did allow for 
both PIS and KMD analysis to be evaluated alongside routine analysis in terms of their ease of use. 
The PIS method was found to be easy to append to previously employed data analysis workflows. 
Having an established list of product ions to be extracted made it simple to apply to routine batches 
containing 30 to 50 samples. KMD analysis, while still easy to perform, proved slightly more time 
consuming in the generation of EICs for each sample based on the results table provided by 
DefectDetect. The implementation of both PIS and KMD techniques alongside routine workflows 
can be completed in approximately 2 to 3 hours (in addition to normal data checking procedures) 
for a routine sequence containing 30 to 50 samples. 
Table 4 provides a summary of the performance of the PIS and KMD techniques. While 
quantitative validation was not completed for this proof-of-concept study, the screening cut-off 
levels show promise for the application of these techniques to routine screening. The estimated cut-
off levels indicate that PIS can detect analytes close to their estimated LODs from validation 
performed by the ARFL for conventional targeted screening. KMD analysis resulted in a higher 
screening cut-off level being estimated. This may be due to the averaging of mass spectral data, 
specifically the averaging of ion intensities, potentially causing low concentration analytes to fall 
outside of the defined filters. 






Screening Cut-off (ng/mL) 
PIS KMD 
Acetyl fentanyl 0.01 0.05 0.1 
Carfentanil 0.05 - 0.1 
Fentanyl 0.01 0.05 0.1 
AH-7921 0.01 0.05 0.1 
U-50488 0.05 0.05 - 
*PIS: Product Ion Searching; KMD: Kendrick mass defect 
 
Given that these techniques are focused on the ‘back-end’ data analysis methods, their sensitivity 
can also be affected by the instrument and analytical methods used. For both techniques, it is 
possible that compounds at concentrations lower than the estimated cut-off levels will be detected, 
however the reliability of detection will be lower. 
Due to the structural diversity of the synthetic opioids, there is no one technique that is best for all 
the compounds analysed. The compounds used for this study were chosen to provide a 
representative panel of compounds that belong to each group of the synthetic opioids. While there 
might be other compounds that do not follow the patterns observed in this study, the results 
obtained demonstrate the importance of using a workflow containing multiple, complimentary 
techniques. In this way, the drawbacks of one technique can be made up for by another, providing a 
more holistic screening for compounds that might be present in a given sample. 
This study has demonstrated the potential of the of PIS and KMD analysis for non-targeted 
screening of synthetic opioids. There is scope for future work to continue to expand the usefulness 
of these techniques to further derivatives to increase their effectiveness. Newer synthetic opioid 
classes, such as the benzimidazole opioids recently reported by Blanckaert et al. 33, can also be 
investigated for inclusion in non-targeted screening workflows implementing these techniques. 
From an operational perspective, further work into the automation of the developed techniques may 
prove valuable to assist their application to routine analysis. 
4. Conclusion 
Non-targeted screening of synthetic opioids can be performed by exploiting common fragmentation 
patterns within the different subclasses of opioids and trends within the KMD of the compounds. 
The blind trials demonstrated the potential of the PIS and KMD analysis techniques in a realistic, 
pseudo-operational context to enhance the screening capabilities for fentanyl analogues. In addition, 
they demonstrated the importance of using the detection techniques as part of a complementary 
workflow to increase the confidence in the detection of compounds of interest. 
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